An Open Label, Randomized, Balanced, Two-treatment, Single Period, Parallel, Single Dose, Subcutaneous Administration, Comparative Pharmacokinetic Study of ADL-018 Injection 150 mg/mL Solution in a Single Dose Pre-filled Autoinjector Compared to ADL-018 Injection 150mg/mL Solution in a Single Dose Pre-filled Syringe in Normal, Healthy, Adult Subjects Under Fasting Conditions
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma; Chronic urticaria; Rhinosinusitis
- Focus Pharmacokinetics
- Sponsors Kashiv BioSciences
Most Recent Events
- 21 Apr 2025 New trial record